Allsup Supports “Walk To End Lupus Now 2022” with LFA Heartland Chapter On Saturday, Sept. 10
August 31, 2022 14:12 ET | Allsup
Belleville, Illinois, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Allsup, the nation’s premier disability representation company®, is proud to be sponsoring the “Walk To End Lupus Now 2022-St. Louis”...
Biogen_Logo_Standard-rgb_R.jpg
The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
July 28, 2022 07:30 ET | Biogen Inc.
Results from Phase 2 LILAC study showed litifilimab significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo as measured by the primary...
exagen-logo-440x386-1.jpg
Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility
July 05, 2022 08:25 ET | Exagen Inc.
SAN DIEGO, July 05, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced new robust, real-world evidence confirming AVISE® testing...
22157.jpg
Global Systemic Lupus Erythematosus (SLE) Market Report 2022-2026: Featuring Pfizer, AstraZeneca, GlaxoSmithKline and Others
June 29, 2022 06:48 ET | Research and Markets
Dublin, June 29, 2022 (GLOBE NEWSWIRE) -- The "Global Systemic Lupus Erythematosus (SLE) Market: Analysis By Product Type, By Route of Administration, By End User, By Region Size and Trends with...
exagen-logo-440x386-1.jpg
Exagen Announces Five-Week Campaign for Lupus Awareness Month
May 01, 2022 12:00 ET | Exagen Inc.
SAN DIEGO, May 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a...
Exagen logo_440x386 (1).jpg
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022
March 08, 2022 16:05 ET | Exagen Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December...
Looped In on Lupus N
Looped In on Lupus Nephritis: American Kidney Fund’s Campaign Focuses on Preventing, Detecting and Managing Lupus Nephritis
February 10, 2022 09:54 ET | American Kidney Fund
ROCKVILLE, Md., Feb. 10, 2022 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announces its Looped In on Lupus Nephritis campaign, which is aimed at improving diagnosis, awareness and...
Exagen logo_440x386 (1).jpg
Exagen Inc. to Participate in the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 02, 2022 16:05 ET | Exagen Inc.
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health,...
Exagen logo_440x386 (1).jpg
Exagen Inc. Expands Coverage with Inland Empire Health Plan, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE Lupus
October 27, 2021 08:25 ET | Exagen Inc.
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE Lupus are a contracted covered...
Exagen logo_440x386 (1).jpg
Exagen Inc. Announces $27.2 Million Debt Refinancing
October 25, 2021 08:25 ET | Exagen Inc.
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that it entered into an amendment to its loan and security...